Candel Therapeutics, Inc.
CADL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001841387
In the last 90 days, Candel Therapeutics, Inc. insiders filed 0 open-market purchases and 2 sales; 137 institutions reported holding it in 13F filings for Q2 2026, worth $518.9M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Candel Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 45 | 1 | 52 | +8 |
| Shares | 5.96M | 823.1K | 6.69M | +1.55M (+30.3%) |
| Value | $37.0M | $5.10M | $46.4M | +$14.5M (+45.6%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (16)
Institutions that held Candel Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 1,125,679 | $7.80M | 0.00% |
| Halter Ferguson Financial Inc. | 304,539 | $2.11M | 1.19% |
| Susquehanna International Group, LLP | 135,455 | $938.7K | 0.00% |
| HB Wealth Management, LLC | 56,658 | $392.6K | 0.00% |
| AQR Capital Management LLC | 20,036 | $138.8K | 0.00% |
| Atom Investors LP | 14,873 | $103.1K | 0.01% |
| MetLife Investment Management | 12,558 | $87.0K | 0.00% |
| Mirae Asset Global ETFs Holdings Ltd. | 10,825 | $75.0K | 0.00% |
| FMR LLC | 6,573 | $45.6K | 0.00% |
| Russell Investments Group, Ltd. | 2,143 | $14.9K | 0.00% |
| Citadel Advisors LLC | 101 | $700 | 0.00% |
| Nisa Investment Advisors, LLC | 78 | $541 | 0.00% |
| GAMMA Investing LLC | 29 | $201 | 0.00% |
| Sterling Capital Management LLC | 20 | $139 | 0.00% |
| National Bank of Canada | 3 | $21 | 0.00% |
| CWM, LLC | 41 | $0 | 0.00% |
Sold out (8)
Institutions that held Candel Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Cubist Systematic Strategies, LLC | 26,121 | $161.9K |
| Advisor Group Holdings, Inc. | 25,800 | $160.0K |
| Virtu Financial LLC | 22,639 | $140.0K |
| Schonfeld Strategic Advisors LLC | 21,452 | $133.0K |
| Renaissance Technologies LLC | 20,600 | $127.7K |
| Alpine Global Management, LLC | 18,761 | $116.3K |
| Point72 (DIFC) Ltd | 4,927 | $30.5K |
| Point72 Asia (Singapore) Pte. Ltd. | 813 | $5.04K |
Not filed for Q3 2024 yet (1)
Institutions that held Candel Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 823,071 | $5.10M |